HCM
CTXR icon

Heights Capital Management’s Citius Pharmaceuticals CTXR Stock Holding History

Heights Capital Management’s Portfolio CTXR Stock Details CTXR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-799,934
Closed -$622K – 269
2025
Q4 		$622K Buy
+799,934
New +$1M 0.22% 83
2025
Q3 		– Sell
-159,898
Closed -$254K – 193
2025
Q2 		$254K Buy
+159,898
New +$146K 0.07% 94

Other funds holding CTXR

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
AAG
Asset Advisory Group Kinnelon, New Jersey $229M AUM
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Heights Capital Management's CTXR Position: Q1 2026 in Review

Heights Capital Management sold out of Citius Pharmaceuticals (CTXR) in Q1 2026, closing a stake of 799,934 shares — an estimated $622K sold.

Heights Capital Management first reported a position in CTXR in Q2 2025 and held it in 2 quarters. The position peaked at $622K in Q4 2025. 38 funds tracked by Wall St. Rank hold CTXR as of Q1 2026.

  • Heights Capital Management reported no remaining Citius Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Heights Capital Management sold 799,934 Citius Pharmaceuticals shares in Q1 2026, an estimated $622K.
  • Heights Capital Management first reported a position in Citius Pharmaceuticals in Q2 2025 and held it in 2 quarters.
  • Heights Capital Management's Citius Pharmaceuticals position peaked at $622K in Q4 2025.
  • 38 funds tracked by Wall St. Rank held Citius Pharmaceuticals as of Q1 2026.

Based on Heights Capital Management's 13F filing for Q1 2026, filed 15 May 2026.